Emanuele Vita, Federico Monaca, Domenico Milardi, Luca Mastrantoni, Alessio Stefani, Edoardo Vergani, Jacopo Russo, Diletta Barone, Ileana Sparagna, Antonio Vitale, Alessandro Scala, Denis Occhipinti, Mariantonietta Di Salvatore, Alfredo Pontecorvi, Giampaolo Tortora, Emilio Bria
BACKGROUND: It is reported that treatment with anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) induces hypogonadism both in male patients with ALK-positive cancer and in murine models. METHODS: In this study, three groups, including an experimental group of male patients with ALK-positive, advanced nonsmall cell lung cancer (ANSCLC) who were receiving alectinib (cohort A), a control group of female patients with ALK-positive ANSCLC who were receiving alectinib (cohort B), and a control group of male patients with ALK-negative ANSCLC (cohort C), prospectively underwent a full hormone assessment for androgen deficiency at 8 weeks after the start of treatment and in case of reported suspected symptoms...
March 28, 2024: Cancer